O
4.54
0.17 (3.89%)
Penutupan Terdahulu | 4.37 |
Buka | 4.39 |
Jumlah Dagangan | 566,151 |
Purata Dagangan (3B) | 900,363 |
Modal Pasaran | 310,632,672 |
Harga / Buku (P/B) | 0.830 |
Julat 52 Minggu | |
Tarikh Pendapatan | 12 Aug 2025 |
EPS Cair (TTM) | -2.00 |
Jumlah Hutang/Ekuiti (D/E MRQ) | 0.30% |
Nisbah Semasa (MRQ) | 15.22 |
Aliran Tunai Operasi (OCF TTM) | -124.83 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -70.86 M |
Pulangan Atas Aset (ROA TTM) | -27.44% |
Pulangan Atas Ekuiti (ROE TTM) | -41.59% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Menurun |
Biotechnology (Global) | Bercampur | Menurun | |
Stok | Olema Pharmaceuticals, Inc. | Menurun | Menurun |
AISkor Stockmoo
0.6
Konsensus Penganalisis | 4.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | 0.5 |
Purata | 0.63 |
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 3.32% |
% Dimiliki oleh Institusi | 98.70% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 30.00 (HC Wainwright & Co., 560.79%) | Beli |
Median | 22.00 (384.58%) | |
Rendah | 18.00 (Goldman Sachs, 296.48%) | Beli |
Purata | 23.33 (413.88%) | |
Jumlah | 3 Beli | |
Harga Purata @ Panggilan | 4.63 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Goldman Sachs | 14 May 2025 | 18.00 (296.48%) | Beli | 4.50 |
Oppenheimer | 14 May 2025 | 22.00 (384.58%) | Beli | 4.50 |
HC Wainwright & Co. | 28 Apr 2025 | 30.00 (560.79%) | Beli | 4.89 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
02 Jul 2025 | Pengumuman | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
03 Jun 2025 | Pengumuman | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
28 May 2025 | Pengumuman | Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting |
21 May 2025 | Pengumuman | Olema Oncology to Participate in Upcoming Investor Conferences |
13 May 2025 | Pengumuman | Olema Oncology Reports First Quarter 2025 Financial and Operating Results |
09 May 2025 | Pengumuman | Olema Oncology to Participate in Upcoming Investor Conferences |
02 May 2025 | Pengumuman | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
25 Apr 2025 | Pengumuman | Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |